A Phase II Study of ZD1839 (Iressa, Gefitinib, NSC 715055) in Advanced Unresectable Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Gefitinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 02 Jun 2009 Actual end date changed from June 2006 to June 2009 as reported by ClinicalTrials.gov.
- 11 Sep 2005 New trial record.